Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of venetoclax for the treatment of this primary cutaneous CD30<sup>+</sup> lymphoproliferative disorder, especially in the setting of severe and refractory disease. Here, TNFRSF8 is linked to lymphoproliferative syndrome.